The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...
By year-end, we are happy to report that we had 107 partners who are running 407 active programs. As our partner pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results